Unmasking Convergent Inflammatory and Oxidative Pathways in Asthma.
作者信息
Tourlakopoulos Konstantinos, Mavrovounis Georgios, Kontopoulou Lamprini, Polyzois Spyros, Pantazopoulos Ioannis, Kirgou Paraskevi, Daniil Zoe, Gourgoulianis Konstantinos I, Kotsiou Ourania S
机构信息
Department of Respiratory Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Department of Nursing, School of Health Sciences, University of Thessaly, Larissa, Greece.
出版信息
Allergy. 2025 Jun;80(6):1801-1806. doi: 10.1111/all.16575. Epub 2025 May 6.
Abstract
摘要
相似文献
1
Unmasking Convergent Inflammatory and Oxidative Pathways in Asthma.揭示哮喘中趋同的炎症和氧化途径
Allergy. 2025 Jun;80(6):1801-1806. doi: 10.1111/all.16575. Epub 2025 May 6.
2
SARS-CoV-2 in Asthmatic Children: Same Consequences in Different Endotypes?哮喘儿童感染严重急性呼吸综合征冠状病毒2：不同内型会有相同后果吗？
Metabolites. 2025 Jun 16;15(6):406. doi: 10.3390/metabo15060406.
3
Exposure to Violence and Asthma Endotypes in Puerto Rican Youth.波多黎各青少年遭受暴力与哮喘内型
Ann Am Thorac Soc. 2025 Jun 23. doi: 10.1513/AnnalsATS.202502-151OC.
4
Asthma and COVID-19: Unveiling Outcome Disparities and Treatment Impact Based on Distinct Endotypes.哮喘与2019冠状病毒病：基于不同内型揭示结局差异及治疗影响
Ann Am Thorac Soc. 2025 Mar;22(3):339-349. doi: 10.1513/AnnalsATS.202405-507OC.
5
Formoterol, the Most Effective Bronchodilator, Has No Anti-Inflammatory nor Metabolic Modulatory Effects in Severe Asthma Induced by Aspergillus fumigatus.福莫特罗，最有效的支气管扩张剂，对烟曲霉诱发的重度哮喘无抗炎及代谢调节作用。
ACS Pharmacol Transl Sci. 2025 May 20;8(6):1556-1566. doi: 10.1021/acsptsci.4c00672. eCollection 2025 Jun 13.
6
Use of biomarkers to identify phenotypes and endotypes of severeasthma.利用生物标志物识别严重哮喘的表型和内型。
Ann Allergy Asthma Immunol. 2018 Oct;121(4):414-420. doi: 10.1016/j.anai.2018.07.029. Epub 2018 Jul 27.
7
Severe asthma phenotypes and endotypes.严重哮喘表型和内型。
Semin Immunol. 2019 Dec;46:101301. doi: 10.1016/j.smim.2019.101301. Epub 2019 Aug 27.
8
Phenotypes and Endotypes in Asthma.哮喘的表型和内型。
Adv Exp Med Biol. 2023;1426:119-142. doi: 10.1007/978-3-031-32259-4_6.
9
Airway molecular endotypes of asthma: dissecting the heterogeneity.哮喘的气道分子内型：剖析其异质性。
Curr Opin Allergy Clin Immunol. 2015 Apr;15(2):163-8. doi: 10.1097/ACI.0000000000000148.
10
Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease.理解哮喘表型、内型和疾病机制。
Clin Rev Allergy Immunol. 2019 Apr;56(2):219-233. doi: 10.1007/s12016-018-8712-1.
本文引用的文献
1
Pathological interplay of NF-κB and M1 macrophages in chronic inflammatory lung diseases.慢性炎症性肺病中NF-κB与M1巨噬细胞的病理相互作用
Pathol Res Pract. 2025 May;269:155903. doi: 10.1016/j.prp.2025.155903. Epub 2025 Mar 7.
2
Characterizing Non-T2 Asthma: Key Pathways and Molecular Implications Indicative of Attenuated Th2 Response.非T2型哮喘的特征：提示Th2反应减弱的关键途径和分子意义
Inflammation. 2024 Oct 28. doi: 10.1007/s10753-024-02159-3.
3
D-ROMs and PAT Tests Reveal a High Level of Oxidative Stress in Patients with Severe Well-Controlled Asthma, and D-ROMs Are Positively Correlated with R20 Values That Indicate Approximate Central Airway Resistance.D-二聚体和PAT检测显示，在病情得到良好控制的重度哮喘患者中存在高水平的氧化应激，且D-二聚体与表示大致中央气道阻力的R20值呈正相关。
J Pers Med. 2023 Jun 2;13(6):943. doi: 10.3390/jpm13060943.
4
T2-Low Asthma: A Discussed but Still Orphan Disease.T2型低哮喘：一种备受讨论但仍属罕见的疾病。
Biomedicines. 2023 Apr 20;11(4):1226. doi: 10.3390/biomedicines11041226.
5
Type-2-low severe asthma endotypes for new treatments: the new asthma frontier.新型治疗方法的2型低重度哮喘内型：哮喘新前沿。
Curr Opin Allergy Clin Immunol. 2023 Jun 1;23(3):199-204. doi: 10.1097/ACI.0000000000000899. Epub 2023 Apr 12.
6
Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma.血清尿激酶型纤溶酶原激活物受体（suPAR）水平可区分中度未控制哮喘与重度哮喘。
J Pers Med. 2022 Oct 28;12(11):1776. doi: 10.3390/jpm12111776.
7
Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma.可溶性尿激酶型纤溶酶原激活物受体（suPAR）与成人哮喘疾病转归的关系
J Asthma Allergy. 2022 May 10;15:579-593. doi: 10.2147/JAA.S356083. eCollection 2022.
8
Molecular mechanisms of oxidative stress in asthma.哮喘中氧化应激的分子机制
Mol Aspects Med. 2022 Jun;85:101026. doi: 10.1016/j.mam.2021.101026. Epub 2021 Oct 6.
9
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.可溶性尿激酶型纤溶酶原激活物受体水平与系统性硬皮病纤维化和血管表现的相关性。
PLoS One. 2021 Feb 22;16(2):e0247256. doi: 10.1371/journal.pone.0247256. eCollection 2021.
10
Biomarkers in asthma: state of the art.哮喘中的生物标志物：最新进展
Asthma Res Pract. 2018 Dec 21;4:10. doi: 10.1186/s40733-018-0047-4. eCollection 2018.
Zotero 插件